|Dr. Christian Martin Itin||CEO & Director||4.34M||N/A||1964|
|Dr. Martin Pule MBBS||Founder, Sr. VP & Chief Scientific Officer||N/A||N/A||1972|
|Mr. Andrew J. Oakley||Sr. VP & CFO||N/A||N/A||1962|
|Mr. Christopher Vann||Sr. VP & COO||N/A||N/A||1965|
|Mr. David Brochu||Sr. VP & Chief Technical Officer||N/A||N/A||1956|
|Dr. Lucinda Crabtree Ph.D.||VP of IR & Corp. Communications||N/A||N/A||N/A|
|Mr. Vishal Mehta||VP & Head of Clinical Operations||N/A||N/A||N/A|
|Mr. Brent Rice||VP & Chief Commercial Officer||N/A||N/A||N/A|
|Mr. Matthias Alder||Sr. VP, Chief Bus. Officer & Sec.||N/A||N/A||1965|
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom.
Autolus Therapeutics plc’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.